Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential

Shuaifeng Yan1,2 · Konstantin Kotschenreuther1 · Shuya Deng3 · David M. Kofler1,4

Received: 12 May 2022 / Revised: 31 August 2022 / Accepted: 17 September 2022 / Published online: 29 September 2022
© The Author(s) 2022

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that mainly affects the joints but also leads to systemic inflammation. Auto-reactivity and dysregulation of self-tolerance are thought to play a vital role in disease onset. In the pathogenesis of autoimmune diseases, disturbed immunosuppressive properties of regulatory T cells contribute to the dysregulation of immune homeostasis. In RA patients, the functions of Treg cells and their frequency are reduced. Therefore, focusing on the re-establishment of self-tolerance by increasing Treg cell frequencies and preventing a loss of function is a promising strategy for the treatment of RA. This approach could be especially beneficial for those patients who do not respond well to current therapies. In this review, we summarize and discuss the current knowledge about the function, differentiation and regulation of Treg cells in RA patients and in animal models of autoimmune arthritis. In addition, we highlight the therapeutic potential as well as the challenges of Treg cell targeting treatment strategies.

Keywords Regulatory T cells · Chimeric antigen receptor · CD4+ T cells · Therapeutic potential · Self-tolerance · Autoimmunity

Introduction

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation in multiple joints, inducing synovitis, cartilage damage and bone erosion. Joint destruction can lead to disability, reduced life quality, reduced life expectancy, and a high burden on the healthcare systems [1, 2]. RA affects about 1% of the population worldwide, occurs at any age and affects women two to three times more often than men [3–5]. Currently, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), targeted synthetic DMARDs, and biological DMARDs are used in clinical practice and can induce remission in many patients. However, in approximately 30% of the patients remission cannot be achieved and RA remains an incurable disease due to the complexity of its pathogenesis [6–9]. Thus, it is necessary to identify new therapeutic targets for the treatment of RA patients, especially for those who do not respond to current therapies.

In the past years, reports about the frequency of Treg cells in the peripheral blood and in the synovial fluid of RA patients have shown contradictory results [10–12]. The differences between the reported results might be due to different approaches used to identify Treg cells. Treg cells seem to be significantly decreased in the peripheral blood at the early stage of RA [13]. Moreover, Treg cells accumulate in the synovial fluid and synovial membrane of inflamed joints of RA patients [14]. The frequency of Treg cells in synovium, peripheral blood and synovial fluid might affect the cell contact-mediated suppressive function of Treg cells in RA [15]. Therefore, both the lack of Treg cells and impaired Treg cell functions contribute to the imbalance between effector T cells and regulatory T cells in RA.
in humans and mice with Foxp3 deficiency can lead to a proliferative autoimmune disorder, whereas the transfer of Foxp3+ Treg cells helps to prevent the development of a fatal lymphoproliferative syndrome with inflammation in many organs caused by the deficiency of foxp3 gene in mice [16]. Lentiviral overexpression of Foxp3 in CD4+ T cells from RA patients induces increased levels of CD25 and CTLA-4 and decreased levels of CD127 and TNF-alpha [17]. Considering the important role of Treg cells in immune homeostasis, reestablishment of self-tolerance by Treg cell therapy seems to be a promising approach to reduce autoimmunity in RA patients. In this review, we will discuss the current knowledge about the function, differentiation and regulation of Treg cells in RA and murine arthritis models. In addition, we will highlight the therapeutic potential and challenges of Treg cells and the progress in this field.

**Suppressive properties of regulatory T cells**

Regulatory T cells are a CD4+ T cell subset that is characterized by expression of its master transcription factor Foxp3 (Forkhead box protein 3), high expression of IL-2 receptor (CD25) and low or negative expression of CD127 [18, 19]. In addition, a small subset of Foxp3 negative CD4+ T cells which is characterized by TGF-beta1 and IL-10 secretion has similar suppressive abilities as Foxp3+ Treg cells [20–22]. This subset is called type 1 regulatory T cells (Tr1 cells). However, the surface markers and transcription factors of this subset have not been fully identified [23]. To date, CD4+CD25hiCD127loFoxp3+ cells remain the most studied Treg group. Our review will, therefore, mainly focus on this cell type, which is crucial for the prevention of autoimmunity despite its low frequency in the peripheral blood [24–27].

**Treg cell transcription factors**

Foxp3 promotes the differentiation of naïve CD4+ T cells into Treg cells and is the most important transcription factor for the development and function of Treg cells [28]. Scurfy mice which are deficient for Foxp3 die early due to highly activated CD4+ T cells and overwhelming proinflammatory cytokine production [29]. Humans with a mutation in the Foxp3 gene can develop the autoimmune inflammatory syndrome IPEX which is characterized by immune dysregulation, polyendocrinopathy and enteropathy [30]. Furthermore, the overexpression of Foxp3 helps to increase the absolute number of Treg cells and CD4+CD25-Foxp3− T cells transfected with Foxp3 show immune suppressive properties and prevent autoimmunity in a mouse model. This evidence indicates that the transcriptional factor Foxp3 is crucial for maintaining the suppressive activity of Treg cells, both in human and mice. However, it seems that Foxp3 is not the only gene required for the maintenance of Treg cell development and function. It has been shown that Helios enhances Treg cell function in cooperation with Foxp3. Helios increases the suppressive function of induced Treg cells and upregulates various Treg cell-related molecules [31]. Moreover, Zheng et al. reported an important role of conserved non-coding DNA sequence (CNS) elements at the Foxp3 locus in the determination of Treg cell frequency, stability and characteristics in mice [32]. Furthermore, CTLA4-Ig and vasoactive intestinal peptide (VIP) are also reported to play a role in the development of Treg cells [33, 34]. However, it remains elusive how these proteins work together to determine Treg cell development and suppressive activity.

**Suppressive mechanisms**

The suppressive activity of Treg cells is mediated by different mechanisms, including cytokine production, direct cell–cell contact suppression and the regulation of antigen-presenting cells (APCs), which induce effector T cells apoptosis and immunosuppression [35–39].

**Cytokines produced by Treg cells**

Treg cells produce a series of cytokines that contribute to their suppressive function. These cytokines include IL-10, TGF-beta and IL-35 (as shown in Fig. 1) [40–44]. In the DBA/1 mouse line, heterozygous (IL-10−/) and homozygous (IL-10−−) mice develop worse arthritis compared to wildtype (WT) mice following induction of collagen type II [45]. Similar results have been observed in C57BL/10 mice and IL-10 deficient mice [46]. Anti-IL-10 antibodies inhibit the expansion of Treg cells in mice with collagen-induced arthritis (CIA), whereas human IL-10 gene transduction can ameliorate the symptoms of established experimental autoimmune arthritis [47, 48]. In addition, it has been reported that Tr1 cells characterized by IL-10 production have the suppressive capacity in mice and humans [49]. Moreover, TGF-beta produced by Treg cells promotes their suppressive function, the expression of Foxp3 and immune homeostasis in vivo [50]. Treg cells also consistently express a high level of TGF-beta on their cell surface after stimulation, which contributes to the inhibition of effector T cells activation and proliferation in both, human and mice [51, 52]. TGF-beta1 produced also mediates immunosuppression by restricting the production of immunoglobulins (Ig) by B cell. These inhibitory effects can be disrupted by the treatment with anti-TGF-beta antibodies [52]. In addition, IL-35 is constitutively expressed in murine Treg cells and contributes to the inhibitory function of Treg cells [43]. Finally, Nakano et al. reported that IL-35 induces suppression of peripheral T cells in RA patients [53]. Taken together, various cytokines...
Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and...
T cells get depleted by strong TCR activation, whereas the cells receiving intermediate TCR activation escape from negative depletion and are able to differentiate into Treg cells [68]. First, TCR stimulation and cytokines drive the CD4+ single positive T cells to upregulation of IL-2R and TNF receptor superfamily members (GITR, OX40, and TNFR2). Next, the expression of Foxp3 is upregulated by recognition of self-antigen-MHC II complexes presented by thymic antigen-presenting cells, which results in the maturation of Treg cells [69–72]. Natural Treg cells are fairly stable and Foxp3 is stabilized by demethylation of the CNS2 region of the Foxp3 locus that leads to recruitment of various transcription factors including Foxp3 itself [73, 74].

**Peripheral and induced Treg cells**

During the development of peripheral Treg cells, naïve CD4+ T cells first migrate into the peripheral blood without any TCR activation. Once stimulated by antigens in the peripheral blood, naïve CD4+ T cells can differentiate into Foxp3+ Treg cells in the presence of both, TGF-beta and IL-2 [75]. Despite their low frequency, peripheral Treg cells can prevent inflammation in barrier tissues [72, 76, 77]. When Treg cells are generated in vitro, they are termed iTreg cells [78]. These cells are also suppressive and can maintain immune homeostasis [79]. Moreover, retinoic acid in the gut is also reported to promote peripheral Treg cells differentiation [78]. Mucosal dendritic cells induce Foxp3+ Treg cells by producing TGF-beta and retinoic acid [80, 81]. The microbial metabolites are short-chain fatty acids (SCFAs) and were reported to facilitate peripheral Treg cell development. However, TGF-beta is required for regulatory effects [82]. It has to be emphasized that iTreg cells are not so stable compared to nTreg cells.

**Other suppressive CD4+ T cell populations**

There is an additional CD4+ T cell subset that mediates immunosuppression in vitro and which attracted a lot of attention in the past years. The cells are characterized by secretion of TGF-beta1 and IL-10 without expressing the transcription factor of Foxp3 [20]. This subset is termed type 1 regulatory T cells (Tr1 cells). However, no specific surface biomarker or transcription factors for this subset have been identified so far, although some promising candidates have been reported [23]. The suppressive mechanisms used by Tr1 cells are similar to those of nTreg cells and include the production of immunosuppressive cytokines, cell–cell contact-mediated suppression, cytotoxicity, and metabolic disruption [23]. IL-10 and other cytokines, including IFN-α, IL-6 and IL-27, are required for the generation of Tr1 cells [83–86]. Importantly, Tr1 Treg cells are found to be less suppressive compared to nTreg cells in the early stage of life, because they fail to rescue IPEX patients with a complete lack of Foxp3 [21]. In addition, it has been also reported that Foxp3+ CD8+ T cells, CD4+CD8− cells and gamma/delta T cells also share some suppressive properties, but no evidence has shown that they play an important role in self-tolerance [30, 87].

**Regulation of Treg cells in rheumatoid arthritis**

Compared to healthy individuals, significant lower frequencies of Treg cells are found in the peripheral blood of patients with RA at an early stage of disease [88]. Moreover, a negative correlation between CD4+CD25highCD127low Treg cell numbers and disease activity as assessed by disease activity score 28 (DAS-28) has been reported [89]. Treg cells are also found in the synovial fluid of RA patients, but their suppressive function is impaired [90]. In a study comparing Treg cell numbers in the synovial fluid of RA patients and osteoarthritis patients, the number of Treg cells were increased in the synovium of RA patients but failed to suppress dendritic cells activation and maturation [91]. In addition, Treg cells in the synovial fluid express higher levels of CTLA-4, GITR, OX40, and Foxp3 despite their impaired ability to suppress the proliferative response of effector T cells [12]. Treg cell plasticity has been reported to allow Treg cells to develop into highly inflammatory Th17 cells under physiological and pathogenic conditions. Interestingly, some Treg cells in the peripheral blood of RA patients produce IL-17 while they maintain their suppressive function [92]. However, it remains unknown if IL-17-producing Treg cells contribute to the pathogenesis of RA. Ex-Foxp3 T cells represent another T cell subset that is found in RA patients. Their phenotype is less stable in inflamed joints with high IL-6 concentration and they do not express Foxp3. These ex-Foxp3 T cells can convert into more osteoclastogenic Th17 cells as compared to Th17 cells which have been differentiated from naïve T cells [93]. Furthermore, deficiency of genes encoding for IL-2, IL-2 receptor (CD25) or CTLA-4 are associated with autoimmune diseases, indicating that these Treg associated cytokines and molecules are important for the prevention of autoimmune disorders [94–97]. In the murine model of collagen-induced arthritis (CIA), the suppressive capacity of Treg cells from mice immunized with complete Freund’s adjuvant (CFA) and collagen type II is impaired. Disruption of Treg cells by anti-CD25 antibodies in these mice has been shown to accelerate the onset of joint inflammation and to increase disease severity. Moreover, iTreg cells from CIA mice upregulate Foxp3 following cell contact with dendritic cells (DC). DC-stimulated Treg cells can prevent effector T cell proliferation and Th17 cell differentiation more efficiently than iTreg cells without DC.
Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and…

stimulation, leading to less severe arthritis [98]. In summary, various studies indicate that dysregulation and deficiency of Treg cells play an important role in the pathogenesis of RA.

**Therapeutic potential of Treg cells**

Treg-based therapies are a promising approach to overcome impaired Treg cell functions and reduced frequencies of Treg cells in RA. The therapeutic potential of Treg cells has been shown in other autoimmune disorders, including experimental autoimmune diabetes and encephalomyelitis [99, 100]. Preclinical research indicates that Treg cell therapies can delay the onset of autoimmune inflammation and reduce graft-versus-host reactions in organ transplantation [101]. Application of type 1 regulatory T cells to symptomatic patients with refractory Crohn’s disease has been proved to be safe and to achieve dose-dependent effects [102]. Moreover, ex vivo expansion of polyclonal Treg cells from patients with early type 1 diabetes resulted in a significant increase in Treg cells numbers, C-peptide levels, prolonged survival of beta-cells, and lower requirement for insulin [103]. In addition, regulatory T-cell therapy proved to be safe in patients who received kidney transplantation, leading to less infectious complications despite an equivalent rejection rate in the first year [104]. Currently, Treg cell therapies are evaluated in several phase I/II clinical trials involving patients with cutaneous lupus, type 1 diabetes, Crohn’s disease, autoimmune hepatitis, and organ transplantation [105]. The results of these trials will help to improve the design of future Treg-based therapies for RA patients. The current strategies to increase Treg cell numbers and their function in vivo and in vitro are shown in Table 1 and in Fig. 2.

**In vivo strategies**

Immunomodulatory drugs targeting Treg cells in vivo represent a possible strategy to improve Treg cell functions and to maintain immune tolerance in RA. This approach includes the application of cytokines as well as the treatment with specific antibodies.

**Preclinical studies using animal models**

A series of preclinical studies revealed that it is possible to increase absolute Treg cell numbers with cytokines or antibodies and to improve Treg cell functions. For example, oral 1,25-dihydroxyvitamin D3 was reported to be able to stabilize Treg cells by enhancing TGF-beta and Foxp3 gene expression, thereby increasing absolute Treg cell numbers and reducing IL-6 expression in mice with lupus-like disease [106]. In addition, short-chain fatty acids (SCFAs) contribute to Treg cell expansion in vitro and in vivo [107]. Furthermore, vitamin C was reported to be necessary for Foxp3 expression [109]. All these drugs prove that the suppressive capacity of Treg cells can be modulated in vivo.

**In vivo strategies targeting Treg cells**

IL-2 receptor alpha chain (CD25) is highly expressed on Foxp3 Treg cells compared to effector CD4+ T cells. Enhancing IL-2 signaling in Treg cells improves the immunosuppression mediated by Treg cells. However, IL-2 signaling is also necessary for the activation and proliferation of proinflammatory T cells. Therefore, some research groups developed immunomodulatory drugs which can prevent the activation of effector T cells by IL-2. Low-dose IL-2 leads to expansion of Treg cell populations and recovery of Treg cell suppression in vivo [110–113].
### Table 1  Overview of common in vivo and in vitro Treg-based therapeutic strategies

| Immunomodulatory interventions | Mechanisms | Effects on Treg cells | Model/disease |
|-------------------------------|------------|-----------------------|---------------|
| **In vivo**                   |            |                       |               |
| Low-dose interleukin-2 [110, 111, 113] | Inflammation and oxidative stress mediators attenuation, Endogenous immune tolerance restoration | Treg cells expansion, activation, and function activation | HCV-induced vasculitis in human, Type 1 diabetes in human, Systemic lupus erythematosus in human |
| Low-dose interleukin-2 [112]   | Promote Treg cells recruitment | Increased Treg cells response | Alopecia areata in human |
| Engineered IL-2 mutein [114, 115], IL-2/IL-2 mAb complex [116, 117] | Increase life-half of IL-2, selective expansion of Treg cells | Selectively activate and expand Treg cells | Mouse colitis model, cynomolgus monkey, type I diabetes, EAE, and xenogeneic graft-versus-host disease |
| IL-4 [118], IL-12 [121]        | Delay donor allograft rejection /Increased Treg cells survival and granzyme expression in Treg cells | Treg cells survival and function promotion | GVHD transplantation Model/− |
| **IL-5 [119]**                | Induce Ag-specific tolerance | Increased antigen-specific Treg cells | Experimental autoimmune neuritis |
| **IL-7 [120]**                | Maintain memory Treg cells in the steady state | mTreg cells maintenance | T cell receptor-alpha-deficient mice |
| **IL-15 [122]**               | Impact the balance of Treg cells and Th17 cells | Successful suppression of Treg cells | Inflammatory bowel disease mouse model |
| IFN-γ [123]                   | Conversion of CD4⁺CD25⁻ T cells to CD4⁺ Treg cells | Treg cells induction | Experimental autoimmune encephalomyelitis mouse model |
| Anti-CD3 antibody [124, 125]   | Selectively deplete pathological cells while expand Foxp³⁺ Treg, Tr1, and Th3 | Probably increased number and function | Multiple autoimmune models |
| **In vitro**                  |            |                       |               |
| Adaptive transfer of Collagen-specific Treg [126, 127, 171] | Damping the proliferation of effector T cells, More Treg cells migrate into LN near the injection joint | Increased antigen-specific Treg number | Collagen-induced arthritis mouse model/ collagen antibody-induced rat arthritis model |
| exogenous regulatory T cells transfusion [128] | Increased proportion of endogenous Treg cells, RASF apoptosis, reduced B cells | Increased exogenous number Treg cells | Collagen-induced arthritis mouse model, RA synovial fibroblast cells |
| Transfer of Ag-specific PSC-Tregs [134] | Suppress the development of IL-17 producing cells in an Ag-dependent fashion | Increased antigen-specific iPSC-Treg cells | Ag-induced arthritis animal model |
| Transfer of induced Treg cells derived from naïve CD4⁺ T cells [135] | Suppress the activation of T cells | Increased absolute number of Treg cells | Chronic colitis mouse model |
| Transfer of ex vivo expanded Treg cells [136–138] | Inhibit effector T cells, inhibition of T cells, B cells, as well as osteoclast-mediated bone destruction | Increased proportion of circulating Treg cells | Patients with acute graft-versus-host disease, CIA mouse model |
Engineered IL-2 has the ability to selectively activate and expand regulatory T cells [114, 115]. Furthermore, IL-2/IL-2 mAb complex also showed potent selective immune regulation on T cells in vivo probably by conformational changes, although the mechanism of this effect remains unclear [116, 117]. In addition, other cytokine-based strategies have the potential to improve Treg cell functions. These cytokines include IL-4, IL-5, IL-7, IL-12, IL-15, and IFN-γ [118–123]. Although these strategies have been tested in mouse models of organ transplantation, type 1 diabetes and other autoimmune disorders, these cytokines have not been used to ameliorate experimental autoimmune arthritis or RA, so far. However, promising results observed in other autoimmune diseases justify further research on the effect of immunosuppressive cytokines on arthritis. Interestingly, selective depletion of effector T cells by anti-CD3 antibodies helps to improve immune tolerance in autoimmune patients and mouse models by preferentially depleting pathogenic cells while preserving Treg cells [124, 125].

**In vitro strategies**

*Preclinical studies involving mouse models*  
Asnagli et al. reported that collagen-induced Treg cells was effective in the treatment of experimental autoimmune arthritis [126]. The efficiency of Treg cell transfer in rats with CIA varies dependent on the stage of disease. In the early stages, Treg cell transfer reduces the symptoms while it shows no effect in later stages because the ability of Treg cells to migrate to lymph nodes is impaired [127]. A recent report has shown that transfusion of exogenous Treg cells in CIA mice can significantly improve the severity of arthritis by increasing the proportion of Treg cells in the spleen and in the peripheral blood [128]. Several phase I/II clinical trials with Treg cells have been performed, so far [101, 129, 130]. Th17 cells are a highly proinflammatory T cell subset in autoimmune arthritis [24, 131–133], Haque et al. have shown that the transfer of functional antigen-specific Treg cells, which were obtained by reprogramming induced pluripotent stem cells, ameliorated the development of CIA by suppressing pro-inflammatory Th17 cells [134]. Ex vivo generated iTreg cells from purified mouse CD4+ T splenocytes showed equivalent suppressive activity as freshly isolated nTreg cells in a mouse model of chronic colitis [135]. Moreover, adoptive cell therapy (ACT) with Treg cells from the peripheral blood, which are expanded in vitro by stimulation with anti-CD3 and anti-CD28 antibodies in the presence of IL-2, has shown promising results. ACT can prevent the development of CIA [136] by inhibiting T cells, B cells and osteoclast-mediated bone destruction [137, 138].

**Clinical trials with Treg cells in RA patients**

Several preclinical studies in arthritis mouse models have shown the effectiveness and safety of adoptive Treg cells and their potential to ameliorate clinical symptoms. Clinical trials have shown that adoptive Treg cell transfer was safe and achievable in kidney transplant recipients (NCT02091232) [104] and was associated with a reduced rate of infectious complications in type 1 diabetes (NCT01210664) [139]. There are some ongoing clinical trials involving patients with other types of diseases, including acute graft-versus-host disease (NCT01795573), steroid-refractory chronic graft-versus-host-disease (NCT03683498), and pemphigus (NCT03239470). These clinical trials may provide useful information for the development of Treg cells-based clinical trials in RA. So far, adoptive Treg cell transfer has not been used in clinical trials involving RA patients.

**Limitations, challenges and opportunities for Treg-based therapies**

Despite recent advances, Treg cell-based therapies remain challenging. First, the number of nTreg cells is low in the peripheral blood and the required number of cells can hardly be obtained without ex vivo expansion of the Treg cell population. Second, iTreg cells are not as stable as nTreg cells. This means that iTreg cells will lose their suppressive function by reducing Foxp3 expression in the absence of stimulating cytokines [140]. However, several pieces of evidence show that it is possible to expand Treg cells which have effective suppressive functions in vitro based on good manufacturing practice-compliant (GMP-compliant) protocols [141–148]. These GMP-compliant protocols can be used for adoptive Treg cell transfer. In addition, Treg cells should be specific enough to target cells. Chimeric antigen receptors can help to increase the specificity, thereby re-directing Treg cells against immunogenic antigens and restore immune tolerance.

**Limited number of available Treg cells in the peripheral blood**  
Lanni et al. reported that freshly isolated Treg cells can be used for clinical applications [149], but the low frequency of Treg cells in the peripheral blood restricts their use in clinical trials. It has been shown that conventional T cells can convert into Treg cells in mice by forced expression of Foxp3. In humans, the situation seems to be by far more complicated as it is not possible to generate potent suppressive human Treg cells in vitro by retroviral gene transfer.
mediated overexpression of Foxp3 [150–153]. However, Allan et al. reported the successful use of lentivirus for the transduction of FoxP3, thereby efficiently converting effector T cells into Treg cells [154]. However, further confirmation is required and safety issues regarding viral gene transfer into human T cells have to be solved. Interestingly, Dijke et al. reported that discarded human thymuses from pediatric cardiac surgery can serve as a new efficient source of Treg cells. These Treg cells are characterized by enhanced survival, stable expression of FoxP3 and immunosuppressive functions [101] (See Table 1).

Instability of Treg cells

Transduction of Foxp3 into iTreg cells seems to be a promising approach to induce stable FoxP3 expression, to stabilize the Treg cell phenotype and to maintain the full suppressive ability of Treg cells [154]. Recently, Honaker et al. used homology-directed repair (HDR)-based gene editing to enforce stable and robust expression of endogenous Foxp3, showing suppressive activity of iTreg cells both in human and mice with inflammatory diseases [155]. The stability of iTreg cells might be important to develop the full potential of adoptive Treg transfer in future clinical trials. However, it remains unclear whether the efficiency of genetically engineered iTreg cells is comparable to freshly isolated ex vivo iTreg cells or peripheral Treg cells [156]. It has also been shown that the transcription factors Helios, Eos, IRF4, Satb1, Lef1, and GATA-1 are necessary to maintain the suppressive property of Treg cells [157–160]. These findings demonstrate the complexity of Treg cell functions and the challenges which have to be faced to obtain suppressive iTreg cells. It has been reported that epigenetic modifications are involved in the regulation of Treg cell stability [161], but the underlying mechanisms remain unclear.

Opportunities for Treg cells expansion

It has been reported that freshly isolated Treg cells can be expanded ex vivo under Treg skewing conditions [162], and expanded polyclonal suppressive human Treg cells can prevent graft rejection [163]. During the past several years, there are some pieces of evidence showing that it is feasible to expand a satisfying amount of Treg cells that keep their suppressive ability in vitro using GMP-compliant protocols (see Table 2). This approach seems promising for future clinical trials in this field. Some reports suggest different approaches, including retroviral gene transfer mediated overexpression of FoxP3 or engineered iTreg cells to increase the stability of their suppressive function. In most reports, Treg cells were expanded from natural Treg cells obtained from peripheral blood mononuclear cells whereas in one of these reports cryopreserved umbilical cord blood was used to obtain naïve Treg cells. Anti-CD3/CD28 beads, IL-2 and rapamycin or everolimus were used in these expansion conditions. It is worth highlighting that Landwehr et al. reported that they used an allogeneic B cell bank for the expansion of allospecific natural Treg cells, which showed a superior suppressive ability compared to polyclonal natural Treg cells [143]. Even though the expansion protocols vary among these reports, they all show that a satisfying amount of Treg cells can be obtained and that Treg cells keep their suppressive function. However, further investigation is required to determine how these Treg cells could contribute to the restoration of immune tolerance in clinical trials.

Antigen-specificity of Treg cells and use of chimeric antigen receptors

Treg cells express a spectrum of molecules that helps them to transmigrate into inflammatory sites, including CCR6, CXCR4 and CXCR5 [164]. Evidence obtained from animal studies shows that antigen-specific Treg cells are more effective than polyclonal Tregs [155, 165–171]. A study about Treg cell transfer in a mouse model of myocardial infarction-induced ventricular remodeling has demonstrated that transferred Treg cells predominantly accumulate in the spleen rather than in inflammatory tissues [172]. Therefore, antigen-specific Treg cells are believed to be more suitable for clinical applications. Recently, we reported the role of post-translational modification of VASP for reduced migration of Treg cells in RA [24]. VASP might serve as a new potential specific target for engineered Treg cells. High VASP expression could increase the migration of Treg cells into inflamed synovial tissues in RA patients. To date, several strategies have been developed to obtain antigen-specific Treg cells: T cell receptor overexpression, antigen-stimulated expansion and chimeric antigen receptors (CAR). However, the first two methods are limited by low cell numbers, complex manufacture procedures and patient-specific TCRs. In contrast, CARs seem to be a promising tool for the generation of antigen-specific Treg cells. Various CARs have been used for the experimental treatment of autoimmune diseases. For example, CD19-CAR transfer was reported to be effective to suppress pathogenic B cells in autoantibody-mediated autoimmune disease. CD19-CAR Treg cells derived from naïve CD4+CD25highCD127lowCD45RA+ cells maintained their suppressive functions, including high expression levels of TGF-beta and Foxp3 as compared to CD19-CAR Treg cells derived from CD4+CD25highCD127lowCD45RO+ memory cells [173].

Recently, CAR-T cells targeting specific citrullinated peptide epitopes, including citrullinated vimentin (cVIM), citrullinated type II collagen (cCOII), citrullinated fibrinogen (cFib), citrullinated tenasin-C (cTNC-5), and cyclocitrulline peptide (CCP-1) were tested in vitro using T cells
### Table 2  Treg cells expanded with good manufacturing practice (GMP)-compatible protocols in human cells

| Evidence | Cell origin | Mechanisms | Time to expand | Expansion conditions | Expansion effects | Suppressive ability | Possible application | Literature |
|----------|-------------|------------|----------------|----------------------|-------------------|---------------------|----------------------|------------|
| 1        | Cryopreserved umbilical cord blood | Naïve Treg cells isolation and expansion in vitro | 16 days | Artificial APC or CD3/CD28 beads, IL-2 | Mean 2092-fold expansion to $1.26\times10^8$ | Effective suppression against responder T cells | Autologous adaptive cell transfer therapy | [141] |
| 2        | Peripheral blood | In vitro expansion | 36 days | Anti-CD3/CD28 beads, rapamycin, IL2 | 300-fold expansion | Effective suppression function | Clinical trials | [142] |
| 3        | Peripheral blood | Expansion of natural Treg by allogeneic activated B cells | 28 days | B cell lines, rapamycin, IL2 | 80- to 120-fold expansion | Superior suppressive ability compared to polyclonal natural Treg cells | Suppressing allogeneic skin graft rejection in vivo | [143] |
| 4        | Peripheral blood | Expansion Treg cells in vitro | 21 days | Anti-CD3/CD28 beads, rapamycin, IL2 | Not available | Retained its suppressive function for at least 1 year | Therapy for inflammatory and autoimmune disorders | [144] |
| 5        | Peripheral blood | mTOR inhibitor Everolimus based expansion | 21 days | Anti-CD3/CD28 beads, everolimus, IL2 | Around 100-fold expansion | Suppression comparable with those induced with rapamycin | Clinical application in transplantation | [146] |
| 6        | Peripheral blood | Expansion of Treg cells in vitro | 28 days | Anti-CD3/CD28 beads, rapamycin, IL2 | 25- to 200-fold increase | Suppressive function restored by expansion | Adoptive therapy based on Treg cells | [147] |
| 7        | Peripheral blood | In vitro expansion | 21 days | Anti-CD3/CD28 beads, IL2 | 107- to 196-fold expansion | Effective suppression against effector cells | Clinical trials for translational research | [148] |
| 8        | Peripheral blood | Expansion in vitro | 19 days | Anti-CD3/CD28 beads, IL2 | 70- to 185-fold expansion | Effective suppression | For mRNA-engineered Treg for further clinical application | [145] |
from CIA mice or RA patients. These CAR-T cells not only specifically recognized and killed anti-CII antibody-secreting B cells from CIA mice but also diminished specific autoreactive B cells in RA patients [174]. Noteworthy, there are individual autoantigen expression profiles in RA patients, making it difficult to develop specific CAR-T cells for a larger cohort of patients. However, it is possible to develop customized CAR-T cells for patients with severe diseases and organ manifestations. Moreover, Whittington et al. reported recently that DR1-CII CAR-T cells can specifically and effectively recognize and kill CD4+ T cells which are specific for the CII autoantigen in vivo in CIA mice. This leads to reduced autoantibody production, decreased collagen II-specific CD4+ T cell response and diminished severity of autoimmune arthritis in mice [175]. Furthermore, HLA-A*02 CAR-Treg cells were generated and have shown to be highly effective in preventing immune responses mediated by HLA-A*02 in both, human and mice [176]. Currently, there is no clear evidence showing that CAR-Treg cells could be used to cure RA, even though the aforementioned specific CAR-T cells seem to be very promising. Therefore, further investigations are need, especially to test the efficacy of CAR-Treg cells in vivo in RA patients and in arthritis mouse models.

In addition, co-stimulation with CD28/CTLA-4/B7 domains plays an important role in the homeostasis and function of Treg cells [177, 178]. The intracellular domain of CD28 is often integrated in CARs along with the intracellular domain of CD3. Dawson et al. reported that co-receptor signaling domains improve the efficacy of CAR-Treg cells [179]. The authors compared ten different co-receptor signaling domain-CARs and analyzed the gene expression profiles and the functions of human Treg cells. They demonstrated that a CAR encoding CD28 is superior to CARs with other intracellular signaling domains, including ICOS, CTLA-4, PD-1, OX40, GITR, 4-1BB, and TNFR2 [179]. Interestingly, 4-1BB and TNFR2 CARs are less effective regulator of the methylation status of TSDR within Foxp3, thereby inducing Treg cells with reduced stability. Furthermore, Boroughs et al. have reported that CD28-based CAR-Treg cells maintain their suppressive function in contrast to 4-1BB-CARs [180]. Due to the enhanced specificity of antigen-specific Treg cells, lower numbers of engineered iTreg cells are needed for adaptive Treg cell transfer as compared to nTreg cells.

The half-life time of CAR-T cells was reported to be relatively short after passive transfer into CIA mice and it was not possible to detect CAR-T cells in mice later than day 10 after adoptive cell transfer [175]. However, CAR-CD8+ Treg cells are still functional and can activate T cells in vivo for at least 80 days [181]. Moreover, CAR-CD4+ Treg cells can still be recruited at least 40 days after transfer into mice with skin grafts [170]. The mechanisms regulating the survival time of CAR-T cells and CAR-Treg cells is not clear yet, but it seems that the half-life time of CAR-Treg cells is superior to the half-life time of CAR-T cells. Further efforts will help to improve antigen-specific Treg transfer and to use CAR Treg cells for clinical application.

Conclusion

Treg cell transfer and maintenance of Treg cell functions is a promising strategy to improve the treatment of RA. Preclinical and clinical trials have demonstrated the efficiency of Treg cell transfer. CAR-Treg cells may be a helpful tool to treat or even cure autoimmune diseases. However, a better understanding of Treg cells and their regulatory mechanisms is still required to improve the clinical application of Treg therapy in RA. The best time point for Treg cell therapies and the optimal dosage of Treg cells or Treg cell promoting drugs need to be determined. Taken together, Treg cell therapies have the potential to revolutionize RA therapy but intensive research is still needed to evaluate and improve this therapeutic approach.

Author contributions SY, KK, SD, and DMK wrote the manuscript. All authors approved the final version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability Not applicable.

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038

 Springer
2. Chang MH, Nigrovic PA (2019) Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight 4(5):1–15
3. Cross M et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316–1322
4. Almutairi K et al (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41(5):863–877
5. Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I Arthritis Rheum 58(1):15–25
6. Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9(10):1245–50
7. Smolen JS et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975
8. Meyer A, Kofler DM (2019) Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation. Cell Mol Immunol 16(9):733–734
9. Lewis MJ et al (2019) Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep 28(9):2455-2470.e5
10. van Amelsfort JM et al (2004) CD4(+)CD25(+) regulatory T cells are enriched in the synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 36(6):428–433
11. Möttönen M et al (2005) CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 140(2):360–367
12. Lawson CA et al (2006) Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45(10):1210–1217
13. Morandi B et al (2014) CD4+CD25(high)CD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints—analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther 16(2):R97
14. Behrens F et al (2007) Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 66(9):1151–1156
15. Huter EN et al (2008) TGF-beta-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur J Immunol 38(7):1814–1821
16. Beavis PA et al (2011) Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci USA 108(40):16717–16722
17. Sakaguchi S et al (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151–64
18. Khattri R et al (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4(4):337–342
19. Vieira PL et al (2004) IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 172(10):5986–5993
20. Gregori S, Goudy KS, Roncarolo MG (2012) The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 3:30
21. Chen Y et al (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265(5176):1237–1240
22. Song Y et al (2021) Tr1 cells as a key regulator for maintaining immune homeostasis in transplantation. Front Immunol 12:671579
23. Yan S et al (2011) Membrane-bound IL-6R is upregulated on Th17 cells and inhibits Treg cell migration by regulating post-translational modification of VASP in autoimmune arthritis. Cell Mol Life Sci 79(1):3
24. Meyer A et al (2021) Kinase activity profiling reveals contribution of G-protein signaling modulator 2 deficiency to impaired regulatory T cell migration in rheumatoid arthritis. J Autoimmun 124:102726
25. Scheinecker C, Göschl L, Bonelli M (2020) Treg cells in health and autoimmune diseases: new insights from single cell analysis. J Autoimmun 110:102376
26. Ko HJ et al (2010) CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population. J Autoimmun 34(2):111–120
27. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061
28. Brunkeow ME et al (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27(1):68–73
29. Sakaguchi S et al (2008) Regulatory T cells and immune tolerance. Cell 133(5):775–787
30. Takatori H et al (2015) Helios enhances treg cell function in cooperation with Foxp3. Arthritis Rheumatol 67(6):1491–1502
31. Zheng Y et al (2010) Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463(7282):808–812
32. Razmara M et al (2008) CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells. Int Immunol 20(4):471–483
33. Gonzalez-Rey E, Delgado M (2007) Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 13(6):241–251
34. Wing JB, Sakaguchi S (2012) Multiple treg suppressive modules and their adaptability. Front Immunol 3:178
35. Shevach EM (2009) Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5):636–645
36. Putnam AL et al (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58(3):652–662
37. Okeke EB, Uzonna JE (2019) The pivotal role of regulatory T cells in the regulation of innate immune cells. Front Immunol 10:680
38. Thornton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188(2):287–296
39. Fahlin L et al (2005) T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 201(5):737–746
40. Hará M et al (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166(6):3789–3796
41. Asseman C et al (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190(7):995–1004
43. Collison LW et al (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566–569
44. Anderson AC et al (2004) IL-10 plays an important role in the homeostatic regulation of the autoreactive repertoire in naive mice. J Immunol 173(2):828–834
45. Finnegan A et al (2003) Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther 5(1):R18-24
46. Johansson AC et al (2001) IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 167(6):3505–12
47. Fellowes R et al (2000) Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Ther 7(11):967–977
48. Park MJ et al (2018) Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice. Sci Rep 8(1):3753
49. Roncarolo MG et al (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50
50. Marie JC et al (2005) Th17 cytokine IL-17A drives IL-23-dependent T helper 17 cell differentiation. Immunity 24(1):11–22
51. Bennett CL et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20–21
52. Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194(5):629–644
53. Nakano S et al (2015) Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54(8):1498–1506
54. Onishi Y et al (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29):10113–10118
55. Liang B et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180(9):5916–5926
56. Fife BT, Pauken KE (2011) The role of the PD-1 pathway in T cell differentiation mediated by retinoic acid. Science 334(6058):1127–1130
57. Goedeke DC et al (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174(4):1783–1786
58. Rupp MC et al (2021) The posttraumatic response of CD4+ regulatory T cells is modulated by direct cell-cell contact via CD40L- and P-selectin-dependent pathways. Cent Eur J Immunol 46(3):283–294
59. de la Rosa M et al (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34(9):2480–2488
60. Bourj MJ et al (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112(2):358–404
61. Borsellino G et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4):1225–1232
62. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414(6866):916–920
63. Roncarolo MG et al (2006) Interleukin-10-producing type 1 regulatory T cells. Annu Rev Immunol 24:212:28–50
64. Campbell DJ, Koch MA (2011) Phenotypic and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11(2):119–130
65. Owen DL, Sjøastad LE, Farrar MA (2019) Regulatory T cell development in the thymus. J Immunol 203(8):2031–2041
66. Savage PA, Klawon DE, Miller CH (2020) Regulatory T cell development. Annu Rev Immunol 38:421–453
67. Buksh F, Wiekmeijer AS, Staal FJ (2017) The development of T cells from stem cells in mice and humans. Future Sci OA 3(3):Fso186
68. Lio CW, Tsai CH (2008) A two-step process for thymic regulatory T cell development. Immunity 28(1):100–111
69. Schuch MD et al (2013) CD4+CD25+ regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29):10113–10118
70. Liang B et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180(9):5916–5926
71. Bennett CL et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20–21
72. Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194(5):629–644
73. Nakano S et al (2015) Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54(8):1498–1506
74. Onishi Y et al (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29):10113–10118
75. Liang B et al (2008) Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180(9):5916–5926
76. Fife BT, Pauken KE (2011) The role of the PD-1 pathway in T cell differentiation mediated by retinoic acid. Science 334(6058):1127–1130
77. Goedeke DC et al (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174(4):1783–1786
78. Rupp MC et al (2021) The posttraumatic response of CD4+ regulatory T cells is modulated by direct cell-cell contact via CD40L- and P-selectin-dependent pathways. Cent Eur J Immunol 46(3):283–294
79. de la Rosa M et al (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34(9):2480–2488
80. de la Rosa M et al (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34(9):2480–2488
81. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414(6866):916–920
82. Roncarolo MG et al (2006) Interleukin-10-producing type 1 regulatory T cells. Annu Rev Immunol 24:212:28–50
83. Bours MJ et al (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. J Autoimmun 204(8):1757–1764
84. Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 158(4):749–763
85. Awasthi A et al (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380–1389
86. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414(6866):916–920
87. Roncarolo MG et al (2006) Interleukin-10-secreting type 1 regulatory T cells. Annu Rev Immunol 24:212:28–50
88. Bours MJ et al (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. J Autoimmun 204(8):1757–1764
89. Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341(6145):569–573
90. Groux H et al (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652):737–742
91. Jin JO, Han X, Yu Q (2013) Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun 40:28–44
92. Awasthi A et al (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380–1389
Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and...
advanced collagen-induced arthritis progress in rats. Immunotherapy 7(3):215–228

128. Li S et al (2020) Therapeutic effect of exogenous regulatory T cells on collagen-induced arthritis and rheumatoid arthritis. Cell Transplant 29:963689720954134

129. Romano M et al (2017) Treg therapy in transplantation: a general overview. Transpl Int 30(8):745–753

130. Vaikunthanathan T et al (2017) Regulatory T cells: tolerance induction in solid organ transplantation. Clin Exp Immunol 189(2):197–210

131. Kotschenreuther K et al (2021) Cannabinoids drive Th17 cell differentiation in patients with autoimmune diseases. Cell Mol Immunol 18(3):764–766

132. Klaser C et al (2019) Prostaglandin receptor EP4 expression by Th17 cells is associated with high disease activity in ankylosing spondylitis. Arthritis Res Ther 21(1):159

133. Meyer A et al (2021) Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. Ann Rheum Dis 80(12):e196

134. Haque M et al (2016) Stem cell-derived tissue-associated regulatory T cells ameliorate the development of autoimmunity. Sci Rep 6:20588

135. Karlsson F et al (2011) Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol 677:47–61

136. Brunstein CG et al (2011) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117(3):1061–1070

137. Morgan ME et al (2005) Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 52(7):2212–2221

138. Zaiss MM et al (2007) Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 56(12):4104–4112

139. Bluestone JA et al (2015) Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 7(315):315ra189

140. Schmidt C et al (2018) Epigenetic mechanisms regulating T-cell responses. J Allergy Clin Immunol 142(3):728–743

141. Seay HR et al (2017) UBD, a downstream element of Foxp3, allows the identification of LGALS3, a new marker of human regulatory T cells. Lab Invest 86(7):724–737

142. Noyan F et al (2017) Prevention of allograft rejection by use of alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25+CD4+ precursors in a thymus-independent process. J Immunol 172(2):923–928

143. Allan SE et al (2005) The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 115(11):3276–3284

144. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

145. Honaker Y et al (2020) Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function. Sci Transl Med 12(546):1–18

146. Rosado-Sánchez I, Levings MK (2020) Building a CAR-Treg: going from the basic to the luxury model. Cell Immunol 358:104220

147. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

148. Lavazza C et al (2022) Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product. J Transl Med 20(1):14

149. Di Ianni M et al (2011) Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14):3921–3928

150. Ockenberg F et al (2006) UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells. Lab Invest 86(7):724–737

151. Yagi H et al (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 16(11):1643–1656

152. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

153. Fu W et al (2012) A multiply redundant genetic switch ‘locks in’ the transcriptional signature of regulatory T cells. Nat Immunol 13(10):972–980

154. Kim HJ et al (2015) Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 350(6258):334–339

155. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

156. Ockenberg F et al (2006) UBD, a downstream element of FOXP3, allows the identification of LGALS3, a new marker of human regulatory T cells. Lab Invest 86(7):724–737

157. Seng A et al (2020) Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells. Blood Adv 4(7):1325–1339

158. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

159. Polansky JK et al (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(9):2685–2694

160. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

161. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

162. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

163. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

164. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

165. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202

166. Allan SE et al (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16(1):194–202
170. MacDonald KG et al (2016) Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 126(4):1413–1424

171. Sun G et al (2018) Adoptive induced antigen-specific Treg cells reverse inflammation in collagen-induced arthritis mouse model. Inflammation 41(2):485–495

172. Matsumoto K et al (2011) Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int Heart J 52(6):382–387

173. Imura Y et al (2020) CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. JCI Insight 5(14):1–16

174. Zhang B et al (2021) In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis 80(2):176–184

175. Whittington KB et al (2022) CD8(+) T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4(+) T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis. J Immunol 208(1):16–26

176. Vimond N et al (2021) Genetic engineering of human and mouse CD4(+) and CD8(+) Tregs using lentiviral vectors encoding chimeric antigen receptors. Mol Ther Methods Clin Dev 20:69–85

177. Bour-Jordan H, Bluestone JA (2009) Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 229(1):41–66

178. Azuma M (2019) Co-signal molecules in T-cell activation: historical overview and perspective. Adv Exp Med Biol 1189:3–23

179. Dawson NAJ et al (2020) Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci Transl Med 12(557):1–16

180. Boroughs AC et al (2019) Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5(8):1–19

181. Boardman DA et al (2017) Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant 17(4):931–943

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.